For patients in Europe, it is increasingly important where their drugs are made

The pandemic has increased patient interest in Europe's role in drug production. New consumer research shows that seven out of ten chronically ill patients want to know where their medicines are made and to make sure European production remains competitive with other continents (71 percent). The vast majority of respondents (84 percent) want governments to support investment in pharmaceutical production in their region, thereby avoiding excessive dependence on non-European countries.

"Europe's overdependence on the production of active pharmaceutical ingredients in Asia became apparent when factories and borders were closed. On the other hand, an approach based solely on individual national strategies will not work in such a closely interconnected and interdependent area as drug supply today. Europe needs to adapt its policy to the new economic and technological realities while strengthening its competitiveness and geopolitical position by remaining open and attracting investment,” Richard Daniell, President of Teva Europe, explained.

Today, 95 percent of Teva's drugs are manufactured in Europe using a global supply line. One of the manufacturers of drugs for the Polish and European markets is the Teva plant in Kraków.

"Over the past ten years, the Teva Group has invested over $70 million in Krakow, in PLN 270 million," Michał Nitka, Teva's CEO for Poland and Central and Eastern Europe, said.

(WBJ)